Toxicity of the polymeric excipients in geriatric polypharmacy

[Display omitted] Geriatric polypharmacy is already a complicated issue in pharmacotherapy as multiple biological and pharmaceutical factors are involved. Given the fact that the geriatric population, in general, takes more than five medications for multiple diseases and most likely takes several su...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2022-06, Vol.622, p.121901-121901, Article 121901
Main Authors: Omidian, Hossein, Babanejad, Niloofar, Mfoafo, Kwadwo, Bertol, Charise, Omidi, Yadollah
Format: Article
Language:English
Subjects:
Excipient impurities
Geriatric medications
Polymeric excipients
Polypharmacy
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Geriatric polypharmacy is already a complicated issue in pharmacotherapy as multiple biological and pharmaceutical factors are involved. Given the fact that the geriatric population, in general, takes more than five medications for multiple diseases and most likely takes several supplements, there is a hidden issue with the types and amounts of the pharmaceutical inactive ingredients (polymers in particular) as they, as well as their impurities, may build up in an ill-performing body beyond their safety levels. In this commentary, we impart on biological factors, the importance of polymers, and the types and amounts of the impurities within each polymeric excipient that can potentially lead to severe pharmacological and biological impacts. Given the complex safety and toxicity issues in polypharmacy, we may need to revisit the safety standards and regulations on the inactive materials that are widely used in geriatric medications.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2022.121901